BEAM * Stock Overview
A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Beam Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$490.80 |
| 52 Week High | US$490.80 |
| 52 Week Low | US$440.00 |
| Beta | 1.86 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| BEAM * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | n/a | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how BEAM * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how BEAM * performed against the MX Market.
Price Volatility
| BEAM * volatility | |
|---|---|
| BEAM * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BEAM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine BEAM *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 472 | John Evans | beamtx.com |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. Fundamentals Summary
| BEAM * fundamental statistics | |
|---|---|
| Market cap | Mex$42.57b |
| Earnings (TTM) | -Mex$2.89b |
| Revenue (TTM) | Mex$7.03b |
6.1x
P/S Ratio-14.8x
P/E RatioIs BEAM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BEAM * income statement (TTM) | |
|---|---|
| Revenue | US$349.64m |
| Cost of Revenue | US$406.19m |
| Gross Profit | -US$56.55m |
| Other Expenses | US$87.04m |
| Earnings | -US$143.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | -16.17% |
| Net Profit Margin | -41.07% |
| Debt/Equity Ratio | 0% |
How did BEAM * perform over the long term?
See historical performance and comparison